Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 246 results found. Search for [ Adar Poonawalla coronavirus vaccine ]

Results 160 to 180 of 246
BusinessToday.In
September 17, 2020
Adar Poonawalla-helmed Serum Institute had partnered with Novavax in August for the production of its coronavirus vaccine. The US drug developer plans to manufacture 2 billion doses annually


BusinessToday.In
September 16, 2020
Coronavirus vaccine trials: While China has four vaccine candidates in third or final stages of clinical trials, there are at least two companies from the United States and one from UK and Germany, which are planning to rollout vaccine before December, if everything goes as per the plan


BusinessToday.In
New Delhi, September 16, 2020
COVID-19 to become seasonal? Herd immunity will decide frequency of outbreak, claims studyScientists have predicted that coronavirus will become a seasonal virus in countries with temperate climates only when herd humanity is attained. Until then, public health measures must be followed to curb the spread of the virus, a review published in Frontiers highlighted. Dr Hassan Zaraket of the American University of Beirut in Lebanon, added, \"COVID-19 is here to stay and it will continue to cause...


Reuters
September 16, 2020
In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India


BusinessToday.In
September 15, 2020
COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief


BusinessToday.In
September 15, 2020
Where the UK has resumed the clinical tests of AstraZeneca's COVID-19 vaccine candidate following a review by the country's drug regulator and an independent safety review committee, trials paused in India, US, and South Africa are yet to resume


BusinessToday.In
September 15, 2020
In India, the Bill and Melinda Gates Foundation has partnered with Serum Institute to ramp up the manufacturing and delivery of coronavirus vaccines


BusinessToday.In
September 15, 2020
The head of the world's largest vaccine manufacturer said that the world will need 15 billion doses of the COVID-19 shot if it is a two-dose vaccine


Reuters
September 15, 2020
Enrollment in AstraZeneca's global trials of the vaccine, which it is developing with researchers at Oxford University, was put on pause on September 6


BusinessToday.In
September 13, 2020
Union Health Minister Harsh Vardhan on Sunday said that he will be the first person to take COVID-19 vaccine so as to dispel the \"trust deficit\" around the same


BusinessToday.In
September 13, 2020
Pfizer says trial is event-based and there are many variables that will ultimately impact read-out timing; adds if trials are successful, these companies would submit vaccines for approval as early as October


BusinessToday.In
September 12, 2020
\"Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials,\" SII CEO Adar Poonawalla said on Saturday


BusinessToday.In
September 12, 2020
Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus


BusinessToday.In
September 12, 2020
DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far


BusinessToday.In
September 11, 2020
Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.


Rajeev Dubey & Manoj Sharma
September 10, 2020
Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India


BusinessToday.In
New Delhi, September 9, 2020
British-Swedish bio-pharmaceutical firm AstraZeneca PLC, working with a team of the University of Oxford, has temporarily paused the clinical trial of its coronavirus vaccine in the UK after one of the volunteers developed an 'unexplained' illness. Serum Institute CEO, Adar Poonawalla, referred to the issue as unrelated and said that it would not impact the vaccine trials in India. Watch the video for more.Also Read: AstraZeneca pauses COVID-19 trials: In which countries are the trials taking place?


BusinessToday.In
September 9, 2020
AstraZeneca vaccine trials halted: Dr. Angela Rasmussen, virologist at Columbia University said that this is exactly why Phase 3 of clinical trials are so important. She added that this might not be a big deal


Manali
September 9, 2020
The initial symptoms of Transverse myelitis include pain in the lower back or sharp, shooting sensations that radiate down the arms, legs, or around the torso


Rajeev Dubey
New Delhi, September 9, 2020
Serum Institute CEO, Adar Poonawalla, told BusinessToday that the Indian trials, which were being conducted on the Oxford vaccine, had not been stopped yet. AstraZeneca PLC, which is working with a team of the University of Oxford, on Wednesday decided to temporarily pause the clinical trial of its coronavirus vaccine after one of the volunteers in the UK developed an 'unexplained' illness. Watch the video for more.Also Read: India coronavirus vaccine trials 'not stopped yet': Serum's Adar Poonawalla after AstraZeneca halts global trials


PAGES 9 OF 13  678910